Alyeska Investment Group
DAWN

Alyeska Investment Group’s Day One Biopharmaceuticals DAWN Stock Holding History

Alyeska Investment Group’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,212,187
Closed -$15.6M – 624
2025
Q3 		$15.6M Sell
2,212,187
-800,000
-27% -$5.5M 0.05% 317
2025
Q2 		$19.6M Sell
3,012,187
-1,047,577
-26% -$7.21M 0.07% 282
2025
Q1 		$32.2M Buy
4,059,764
+1,547,577
+62% +$16.7M 0.13% 194
2024
Q4 		$31.8M Buy
+2,512,187
New +$35M 0.12% 201
2024
Q1 		– Sell
-390,167
Closed -$5.7M – 499
2023
Q4 		$5.7M Hold
390,167
– – 0.04% 300
2023
Q3 		$4.79M Hold
390,167
– – 0.03% 345
2023
Q2 		$4.66M Buy
390,167
+125,000
+47% +$1.63M 0.03% 339
2023
Q1 		$3.55M Buy
265,167
+121,949
+85% +$2.38M 0.03% 321
2022
Q4 		$3.08M Buy
143,218
+1,075
+0.8% +$22K 0.03% 291
2022
Q3 		$2.85M Sell
142,143
-75,000
-35% -$1.6M 0.03% 299
2022
Q2 		$3.89M Buy
217,143
+113,943
+110% +$1.18M 0.04% 326
2022
Q1 		$1.02M Hold
103,200
– – 0.01% 492
2021
Q4 		$1.74M Hold
103,200
– – 0.02% 461
2021
Q3 		$2.45M Hold
103,200
– – 0.03% 470
2021
Q2 		$2.35M Buy
+103,200
New +$2.15M 0.03% 491

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group's DAWN Position: Q4 2025 in Review

Alyeska Investment Group sold out of Day One Biopharmaceuticals (DAWN) in Q4 2025, closing a stake of 2,212,187 shares — an estimated $15.6M sold.

Alyeska Investment Group first reported a position in DAWN in Q2 2021 and held it in 15 quarters. The position peaked at $32.2M in Q1 2025. 183 funds tracked by Wall St. Rank hold DAWN as of Q4 2025.

  • Alyeska Investment Group reported no remaining Day One Biopharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 2,212,187 Day One Biopharmaceuticals shares in Q4 2025, an estimated $15.6M.
  • Alyeska Investment Group first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 15 quarters.
  • Alyeska Investment Group's Day One Biopharmaceuticals position peaked at $32.2M in Q1 2025.
  • 183 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2025.

Based on Alyeska Investment Group's 13F filing for Q4 2025, filed 13 Feb 2026.